CARDIAC PACEMAKERS


Associated tags: Patient, Bradycardia, Skin, Heart, Seniors, Cardiac electrophysiology, Medical device, Arrhythmia, Longevity, Tesla, Physician, Standard of care, MicroPort, MRI, National Association Medical Staff Services, Quality of life, Atrial fibrillation, Vega, Workflow, Infection, Nanotechnology, Consumer, Other Science

FDA Approves Next Generation MicroPort CRM AlizeaTM and CeleaTM Pacemaker Systems

Retrieved on: 
Thursday, May 18, 2023
Seniors, Nanotechnology, Other Science, Pharmaceutical, Research, Software, Medical Devices, Hardware, Consumer, Data Management, Science, Technology, Clinical Trials, Cardiology, General Health, FDA, Biotechnology, Health, Infection, Cardiac electrophysiology, Workflow, Vega, Atrial fibrillation, Quality of life, National Association Medical Staff Services, MRI, MicroPort, Patient, Standard of care, Physician, Risk, Tesla, Longevity, Arrhythmia, Medical device, CRM

AlizeaTM and CeleaTM feature the AutoMRI mode, a groundbreaking algorithm invented by MicroPort CRM, that increases patients’ safety and quality of life when undergoing an MRI examination.

Key Points: 
  • AlizeaTM and CeleaTM feature the AutoMRI mode, a groundbreaking algorithm invented by MicroPort CRM, that increases patients’ safety and quality of life when undergoing an MRI examination.
  • Patients only need to visit their cardiologist once within ten days before their MRI scan to activate the MRI mode.
  • Patients implanted with AlizeaTM or CeleaTM are provided with the SmartView ConnectTM home monitor, which is placed next to their bed.
  • The approval of AlizeaTM, CeleaTM, and associated products is the latest in a number of FDA approvals for MicroPort in the U.S. Last year, MicroPort’s EasyFinderTM cardiac electrophysiology diagnostic catheters and PathBuilderTM transseptal puncture products received FDA approvals and will be distributed by the MicroPort CRM organization.